Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer

Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer

Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nicole Scherr, Raphael Bieri, Sangeeta S. Thomas, Aurélie Chauffour, Nitin Pal Kalia, Paul Schneide, Marie-Thérèse Ruf, Araceli Lamelas, Malathy S. S. Manimekalai, Gerhard Grüber, Norihisa Ishii, Koichi Suzuki, Marcel Tanner, Garrett C. Moraski, Marvin J. Miller, Matthias Witschel, Vincent Jarlier, Gerd Pluschke, Kevin Pethe
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/ead11814b4ee465d85398bdcb2064c81
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising therapeutic candidate for BU.

Ejemplares similares